Polus BioPharm Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was KRW 360.54 million compared to KRW 1,076.51 million a year ago. Basic loss per share from continuing operations was KRW 8 compared to KRW 27 a year ago. Basic loss per share was KRW 8 compared to KRW 27 a year ago. For the nine months, sales was KRW 0.00023 million compared to negative sales of KRW 0.00031 million a year ago. Net loss was KRW 599.9 million compared to KRW 2,701.16 million a year ago. Basic loss per share from continuing operations was KRW 13 compared to KRW 69 a year ago. Basic loss per share was KRW 13 compared to KRW 69 a year ago.